Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Review of vedolizumab for the treatment of ulcerative colitis.

Literature DB >> 26855816

Review of vedolizumab for the treatment of ulcerative colitis.

Abstract

The review summarises the key data on the efficacy and the safety of vedolizumab in the management of ulcerative colitis.

Entities: Chemical Disease

Keywords: Biological therapy; Pharmacology; Safety and efficacy; Ulcerative colitis; Vedolizumab

Year: 2016 PMID： 26855816 PMCID： PMC4734943 DOI： 10.4292/wjgpt.v7.i1.107

Source DB: PubMed Journal: World J Gastrointest Pharmacol Ther ISSN： 2150-5349

13 in total

1. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.

Authors: Asit Parikh; Timothy Leach; Tim Wyant; Catherine Scholz; Serap Sankoh; Diane R Mould; Terry Ponich; Irving Fox; Brian G Feagan
Journal: Inflamm Bowel Dis Date: 2011-12-06 Impact factor: 5.325

Review 2. Targeting leukocyte integrins in human diseases.

Authors: Karyn Yonekawa; John M Harlan
Journal: J Leukoc Biol Date: 2004-11-17 Impact factor: 4.962

3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors: Gary Bloomgren; Sandra Richman; Christophe Hotermans; Meena Subramanyam; Susan Goelz; Amy Natarajan; Sophia Lee; Tatiana Plavina; James V Scanlon; Alfred Sandrock; Carmen Bozic
Journal: N Engl J Med Date: 2012-05-17 Impact factor: 91.245

4. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

Authors: Brian G Feagan; Gordon R Greenberg; Gary Wild; Richard N Fedorak; Pierre Paré; John W D McDonald; Rejean Dubé; Albert Cohen; A Hillary Steinhart; Steven Landau; Rasha A Aguzzi; Irving H Fox; Margaret K Vandervoort
Journal: N Engl J Med Date: 2005-06-16 Impact factor: 91.245

5. Inhibition of leukocyte trafficking in inflammatory bowel disease.

Authors: Fabio Cominelli
Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245

6. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7.

Authors: P E Hesterberg; D Winsor-Hines; M J Briskin; D Soler-Ferran; C Merrill; C R Mackay; W Newman; D J Ringler
Journal: Gastroenterology Date: 1996-11 Impact factor: 22.682

7. Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245

8. Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Authors: Herbert Tilg; Arthur Kaser
Journal: Curr Opin Investig Drugs Date: 2010-11

Review 9. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis.

Authors: Khurram J Khan; Marla C Dubinsky; Alexander C Ford; Thomas A Ullman; Nicholas J Talley; Paul Moayyedi
Journal: Am J Gastroenterol Date: 2011-03-15 Impact factor: 10.864

10. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Authors: Stephan R Targan; Brian G Feagan; Richard N Fedorak; Bret A Lashner; Remo Panaccione; Daniel H Present; Martina E Spehlmann; Paul J Rutgeerts; Zsolt Tulassay; Miroslava Volfova; Douglas C Wolf; Chito Hernandez; Jeffrey Bornstein; William J Sandborn
Journal: Gastroenterology Date: 2007-03-21 Impact factor: 22.682

4 in total